The Impact of Age on Mortality in Chronic Haemodialysis Population with COVID-19
| Autor: | Patricia de Sequera, Amir Shabaka, Silvia Benito, Luis Sanchez-Cámara, Nestor Toapanta, A. Vergara, María Carmen Ruiz, Emilio Sánchez, Andrés Villegas, María José Soler, Mireia Molina-Van den Bosch, Joaquin Manrique, Inés Aragoncillo |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Vergara A, Toapanta N, Soler MJ] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Nephrology Research Group, Vall d’Hebrón Research Institute, REDinREN, 08035 Barcelona, Spain. [Molina-Van den Bosch M] Nephrology Research Group, Vall d’Hebrón Research Institute, REDinREN, 08035 Barcelona, Spain. [Villegas A] Nephrology Department, Germans Trias i Pujol University Hospital, 08916 Badalona, Spain. [Sánchez-Cámara L] Nephrology Department, Fundación para la Investigación Biomédica Gregorio Marañón, 28007 Madrid, Spain. [Sequera P] Nephrology Department, Infanta Leonor University Hospital, 28031 Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19) Population 030232 urology & nephrology 030204 cardiovascular system & hematology elderly Article 03 medical and health sciences 0302 clinical medicine Internal medicine virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] Medicine Chronic hemodialysis Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Renal Insufficiency Chronic [DISEASES] education Therapeutics::Renal Replacement Therapy::Renal Dialysis [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT] Otros calificadores::/terapia [Otros calificadores] personas::Grupos de Edad::adulto::anciano [DENOMINACIONES DE GRUPOS] COVID-19 (Malaltia) - Complicacions education.field_of_study business.industry Proportional hazards model SARS-CoV-2 Hazard ratio enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales::insuficiencia renal::insuficiencia renal crónica [ENFERMEDADES] terapéutica::tratamiento de reemplazo renal::diálisis renal [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS] COVID-19 Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] General Medicine Other subheadings::/therapy [Other subheadings] medicine.disease mortality Hemodiàlisi Vaccination haemodialysis Pneumonia Persons::Age Groups::Adult::Aged [NAMED GROUPS] business Insuficiència renal crònica - Tractament Kidney disease |
| Zdroj: | Scientia Journal of Clinical Medicine Journal of Clinical Medicine, Vol 10, Iss 3022, p 3022 (2021) Volume 10 Issue 14 |
| Popis: | Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Hemodiàlisi; Mortalitat Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Hemodiálisis; Mortalidad Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Haemodialysis; Mortality Age and chronic kidney disease have been described as mortality risk factors for coronavirus disease 2019 (COVID-19). Currently, an important percentage of patients in haemodialysis are elderly. Herein, we investigated the impact of age on mortality among haemodialysis patients with COVID-19. Data was obtained from the Spanish COVID-19 chronic kidney disease (CKD) Working Group Registry. From 18 March 2020 to 27 August 2020, 930 patients on haemodialysis affected by COVID-19 were included in the Registry. A total of 254 patients were under 65 years old and 676 were 65 years or older (elderly group). Mortality was 25.1% higher (95% CI: 22.2–28.0%) in the elderly as compared to the non-elderly group. Death from COVID-19 was increased 6.2-fold in haemodialysis patients as compared to the mortality in the general population in a similar time frame. In the multivariate Cox regression analysis, age (hazard ratio (HR) 1.59, 95% CI: 1.31–1.93), dyspnea at presentation (HR 1.51, 95% CI: 1.11–2.04), pneumonia (HR 1.74, 95% CI: 1.10–2.73) and admission to hospital (HR 4.00, 95% CI: 1.83–8.70) were identified as independent mortality risk factors in the elderly haemodialysis population. Treatment with glucocorticoids reduced the risk of death (HR 0.68, 95% CI: 0.48–0.96). In conclusion, mortality is dramatically increased in elderly haemodialysis patients with COVID-19. Our results suggest that this high risk population should be prioritized in terms of protection and vaccination. The authors are current recipients of FONDOS DE INVESTIGACIÓN SANITARIA—FEDER (ISCIII) PI17/00257, REDINREN RD16/0009/0030, RD/16/0009/0026, and EIN2020-112338. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|